X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (312) 312
Publication (53) 53
Book / eBook (5) 5
Conference Proceeding (5) 5
Web Resource (2) 2
Book Chapter (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (201) 201
female (143) 143
male (140) 140
middle aged (137) 137
hematology (126) 126
adult (119) 119
index medicus (111) 111
aged (90) 90
oncology (76) 76
treatment outcome (57) 57
adolescent (51) 51
antineoplastic combined chemotherapy protocols - therapeutic use (47) 47
chemotherapy (46) 46
transplantation (42) 42
therapy (41) 41
hematopoietic stem cell transplantation (39) 39
aged, 80 and over (36) 36
disease-free survival (33) 33
transplantation, autologous (33) 33
stem cells (30) 30
cancer (28) 28
survival (28) 28
young adult (28) 28
transplantation, homologous (26) 26
antineoplastic agents - therapeutic use (25) 25
antineoplastic combined chemotherapy protocols - adverse effects (24) 24
care and treatment (24) 24
prognosis (24) 24
chronic myelogenous leukemia (21) 21
recurrence (21) 21
combined modality therapy (20) 20
leukemia (20) 20
survival rate (20) 20
antineoplastic combined chemotherapy protocols - administration & dosage (19) 19
retrospective studies (19) 19
stem cell transplantation (19) 19
analysis (18) 18
disease (18) 18
follow-up studies (18) 18
remission induction (18) 18
rituximab (18) 18
gene expression (17) 17
antineoplastic agents - administration & dosage (16) 16
lymphomas (16) 16
relapse (16) 16
research (16) 16
stem-cell transplantation (16) 16
abridged index medicus (15) 15
bone marrow (15) 15
cyclophosphamide - administration & dosage (15) 15
expression (15) 15
genetic aspects (15) 15
hodgkin disease - therapy (15) 15
risk factors (15) 15
survival analysis (15) 15
child (14) 14
health aspects (14) 14
hematology, oncology and palliative medicine (14) 14
bone marrow transplantation (13) 13
cells (13) 13
cyclophosphamide (13) 13
multiple myeloma - drug therapy (13) 13
neoplasm staging (13) 13
patients (13) 13
time factors (13) 13
transplantation conditioning - methods (13) 13
tumors (13) 13
bone-marrow-transplantation (12) 12
chronic myeloid leukemia (12) 12
cytarabine - administration & dosage (12) 12
follow-up (12) 12
hematopoietic stem cells (12) 12
italy (12) 12
leukemia, myelogenous, chronic, bcr-abl positive - therapy (12) 12
multiple myeloma - mortality (12) 12
mutation (12) 12
prednisone - administration & dosage (12) 12
remission (12) 12
thalidomide - administration & dosage (12) 12
trial (12) 12
vidarabine - analogs & derivatives (12) 12
acute myeloid leukemia (11) 11
biology (11) 11
blood (11) 11
child, preschool (11) 11
disease progression (11) 11
doxorubicin - administration & dosage (11) 11
gene expression profiling (11) 11
genes (11) 11
kaplan-meier estimate (11) 11
medicine (11) 11
risk (11) 11
salvage therapy (11) 11
transplants & implants (11) 11
vincristine - administration & dosage (11) 11
bone-marrow transplantation (10) 10
bortezomib (10) 10
elderly-patients (10) 10
hematopoietic stem cell transplantation - methods (10) 10
lymphoma (10) 10
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2001, 1, ISBN 185317890X, xv, 528
In this volume, an international team of experts in chronic myeloid leukemia share their expertise. In particular, they contribute their insights on the latest... 
Treatment | Leukemia, Myeloid | Acute myeloid leukemia | therapy | Clinical & internal medicine | Acute myelocytic leukaemia | Hematology | Oncology | Acute myelocytic leukemia
Book
1995, Clinical drug investigation, Volume 9, suppl. 2., 60
Book
British Journal of Haematology, ISSN 0007-1048, 03/2014, Volume 164, Issue 5, pp. 710 - 716
Summary 90Yttrium (90Y)‐Ibritumomab‐Tiuxetan combines the targeting advantage of a monoclonal antibody with the radiosensitivity of Follicular Lymphoma (FL).... 
follicular lymphoma | high complete remission rate | (90Y)‐Ibritumomab‐Tiuxetan | High complete remission rate | Follicular lymphoma | Y)-Ibritumomab-Tiuxetan | Rare earth metals | Medicine, Experimental | Medical research | Lymphomas
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 2, pp. 111 - 121
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 470 - 470
Abstract Background: Rituximab (R) plus CHOP (R-CHOP) is standard-of-care treatment for previously untreated diffuse large B-cell lymphoma (DLBCL).... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2015, Volume 373, Issue 18, pp. 1733 - 1747
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 673 - 673
Abstract Background For the past 20 years, high-dose therapy plus autologous stem cell transplant (ASCT) has been the standard of care for patients (pts) with... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 1755 - 1755
Abstract Backgrounds: Treatment of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not eligible to high dose therapy represents... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 8, pp. 986 - 993
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. In this randomized, open-label,... 
LOW-DOSE WARFARIN | DEXAMETHASONE | THERAPY | VENOUS THROMBOEMBOLISM | ONCOLOGY | DEEP-VEIN THROMBOSIS | PREDNISONE PLUS THALIDOMIDE | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Warfarin - adverse effects | Male | Antineoplastic Agents - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Multiple Myeloma - drug therapy | Thromboembolism - prevention & control | Time Factors | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Cardiovascular Diseases - mortality | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Risk Assessment | Multiple Myeloma - complications | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Thromboembolism - etiology | Thromboembolism - mortality | Thalidomide - administration & dosage | Anticoagulants - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Hemorrhage - chemically induced
Journal Article
The Lancet, ISSN 0140-6736, 06/2002, Volume 359, Issue 9323, pp. 2065 - 2071
High-dose chemotherapy followed by transplantation of autologous haemopoietic stem cells (BEAMHSCT) is frequently used to treat patients with relapsed... 
SALVAGE CHEMOTHERAPY | ADULT PATIENTS | MEDICINE, GENERAL & INTERNAL | THERAPY | BONE-MARROW-TRANSPLANTATION | 1ST RELAPSE | COMBINATION CHEMOTHERAPY | REGIMEN | LYMPHOMA | CYTOREDUCTION | BLOOD | Recurrence | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Cytarabine - adverse effects | Melphalan - therapeutic use | Cause of Death | Carmustine - therapeutic use | Melphalan - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Carmustine - adverse effects | Dexamethasone - administration & dosage | Etoposide - adverse effects | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Etoposide - therapeutic use | Cytarabine - administration & dosage | Dexamethasone - therapeutic use | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Salvage Therapy - methods | Carmustine - administration & dosage | Evaluation | Chemotherapy | Transplantation | Hodgkin's disease | Hematopoietic stem cells | Lymphomas | Transplants & implants | Clinical outcomes | Stem cells | Dual energy X-ray absorptiometry | Autografts | Dexamethasone | Medical treatment | Etoposide | Stem cell transplantation | Infections | Patients | Blood | Abdomen | Randomization | Cytarabine | Biopsy | Medical prognosis | Failure analysis | Melphalan | Bone marrow | Remission | Stratigraphy
Journal Article
Blood, ISSN 0006-4971, 10/2010, Volume 116, Issue 17, pp. 3171 - 3179
Journal Article